Venture capital allocations in the biopharmaceutical sector have stabilized around targeted RNA delivery systems and precision oncology. Private equity firms are demanding higher clinical proof-of-concept thresholds before participating in Series B rounds.
Clinical Efficiency Metrics
Pharmaceutical companies are integrating machine learning models into clinical trial candidate selection, shortening Phase I timelines by an average of 14 percent year-over-year.